{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T16:01:50Z","timestamp":1720627310244},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ijid.2016.07.013","type":"journal-article","created":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T01:44:10Z","timestamp":1469238250000},"page":"21-22","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["When should antiviral drugs be used for the patient with an Ebola virus infection?"],"prefix":"10.1016","volume":"50","author":[{"given":"Shu","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2016.07.013_bib0055","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijid.2016.02.419","article-title":"Pharmacophore modeling, database mining and biological evaluation to identify novel structurally diverse compounds as potential anti-Ebola drugs","volume":"45","author":"Kant","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2016.07.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw256","article-title":"Use of post-exposure prophylaxis after occupational exposure to Zaire Ebolavirus","author":"Wong","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2016.07.013_bib0065","doi-asserted-by":"crossref","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2016.07.013_bib0070","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2016.07.013_bib0075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/cid\/civ334","article-title":"The Use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States","volume":"61","author":"Kraft","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2016.07.013_bib0080","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1128\/JVI.78.8.4330-4341.2004","article-title":"Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome","volume":"78","author":"Towner","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2016.07.013_bib0085","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1371\/journal.pntd.0000837","article-title":"Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis","volume":"4","author":"Wauquier","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2016.07.013_bib0090","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/infdis\/jiu088","article-title":"Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome","volume":"210","author":"McElroy","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2016.07.013_bib0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2015.04.019","article-title":"Treating Ebola patients: a \u2018bottom up\u2019 approach using generic statins and angiotensin receptor blockers","volume":"36","author":"Fedson","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2016.07.013_bib0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40249-015-0055-z","article-title":"Possible FDA-approved drugs to treat Ebola virus infection","volume":"4","author":"Yuan","year":"2015","journal-title":"Infect Dis Poverty"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971216311201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971216311201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T04:28:35Z","timestamp":1536553715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971216311201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":10,"alternative-id":["S1201971216311201"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2016.07.013","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When should antiviral drugs be used for the patient with an Ebola virus infection?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2016.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}